
Gary M Ansel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7474072/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Three-Year Outcomes From the LIBERTY 360 Study of Endovascular Interventions for Peripheral Artery Disease Stratified by Rutherford Category. Journal of Endovascular Therapy, 2021, 28, 262-274.	1.5	14
2	Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. CardioVascular and Interventional Radiology, 2021, 44, 196-206.	2.0	7
3	Characteristics and Outcomes of Patients With Diabetes Mellitus Undergoing Peripheral Vascular Intervention for Infrainguinal Symptomatic Peripheral Artery Disease. Vascular and Endovascular Surgery, 2021, 55, 124-134.	0.7	7
4	Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The <scp>VIVA REALITY</scp> study. Catheterization and Cardiovascular Interventions, 2021, 98, 549-558.	1.7	33
5	Time for pulmonary embolism alert. Catheterization and Cardiovascular Interventions, 2021, 97, 1438-1439.	1.7	0
6	Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices. CardioVascular and Interventional Radiology, 2020, 43, 8-19.	2.0	47
7	Final Two-Year Outcomes for the Sentry Bioconvertible Inferior Vena Cava Filter in Patients Requiring Temporary Protection from Pulmonary Embolism. Journal of Vascular and Interventional Radiology, 2020, 31, 221-230.e3.	0.5	15
8	EDITORIAL: The Bias of Seeing What You Look For. Cardiovascular Revascularization Medicine, 2020, 21, 108-109.	0.8	0
9	The impact of chronic kidney disease on outcomes following peripheral vascular intervention. Clinical Cardiology, 2020, 43, 1308-1316.	1.8	3
10	Paclitaxel exposure: Longâ€term safety and effectiveness of a drug oated balloon for claudication in pooled randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, 1087-1099.	1.7	23
11	Carotid Artery Stenting in Asymptomatic CarotidÂArtery Stenosis. Journal of the American College of Cardiology, 2020, 75, 648-656.	2.8	12
12	Prevalence and predictors of elevated central venous pressure and obstructive sleep apnea in patients with lower extremity chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 775-782.	1.6	3
13	Pedal access: Put the "pedal to the metal―or drive with caution?. Catheterization and Cardiovascular Interventions, 2019, 93, 1315-1316.	1.7	0
14	Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS. CVIR Endovascular, 2019, 2, 25.	1.1	4
15	The Clinical Rationale for the Sentry Bioconvertible Inferior Vena Cava Filter for the Prevention of Pulmonary Embolism. International Journal of Vascular Medicine, 2019, 2019, 1-15.	1.0	5
16	One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. Journal of Endovascular Therapy, 2019, 26, 143-154.	1.5	35
17	Mortality Not Correlated With PaclitaxelÂExposure. Journal of the American College of Cardiology, 2019, 73, 2550-2563.	2.8	195
18	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. Circulation: Cardiovascular Interventions, 2019, 12, e007730.	3.9	10

GARY M ANSEL

#	Article	IF	CITATIONS
19	Drug-coated balloons versus drug-eluting stents in the femoropopliteal artery: comparing apples to oranges?. Journal of Cardiovascular Surgery, 2019, 60, 456-459.	0.6	1
20	Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries. Journal of Endovascular Therapy, 2018, 25, 295-301.	1.5	22
21	Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Clobal Study. Journal of Endovascular Therapy, 2018, 25, 673-682.	1.5	21
22	One-Year Analysis of the Prospective Multicenter SENTRY Clinical Trial: Safety and Effectiveness ofÂthe Novate Sentry Bioconvertible Inferior Vena Cava Filter. Journal of Vascular and Interventional Radiology, 2018, 29, 1350-1361.e4.	0.5	29
23	Percutaneous Endovascular Aortic Aneurysm Repair for Abdominal Aortic Aneurysm. Current Cardiology Reports, 2018, 20, 79.	2.9	14
24	Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb Ischemia (CLI) ― A Joint USA-Japanese Perspective ―. Circulation Journal, 2018, 82, 2233-2239.	1.6	7
25	The Italian stallions of <scp>CLI</scp> "value care―delivery. Catheterization and Cardiovascular Interventions, 2017, 89, 921-922.	1.7	0
26	A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. Journal of Endovascular Therapy, 2017, 24, 499-503.	1.5	6
27	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation, 2017, 135, 2534-2555.	1.6	136
28	Patientâ€level metaâ€analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. Catheterization and Cardiovascular Interventions, 2017, 89, 1250-1256.	1.7	20
29	Patterns of restenosis for the <scp>SFA</scp> : The second step on a long journey. Catheterization and Cardiovascular Interventions, 2017, 90, 647-647.	1.7	1
30	Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation, 2017, 136, 1102-1113.	1.6	175
31	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. Circulation, 2016, 133, 1472-1483.	1.6	426
32	Helical Centerline Stent Improves Patency. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	30
33	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. European Heart Journal, 2016, 37, 1096-1103.	2.2	73
34	The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. American Heart Journal, 2016, 174, 14-21.	2.7	20
35	Treating on the edge. Catheterization and Cardiovascular Interventions, 2015, 86, 499-500.	1.7	Ο
36	A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention. Journal of Endovascular Therapy, 2015, 22, 261-268.	1.5	16

GARY M ANSEL

#	Article	IF	CITATIONS
37	Do not rock the BOAT: The latest atherectomy device improvement trial. Catheterization and Cardiovascular Interventions, 2014, 84, 245-245.	1.7	0
38	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2013, 61, 2417-2427.	2.8	307
39	Keep out of jail: The reason to limit stent usage for the common femoral artery bifurcation. Catheterization and Cardiovascular Interventions, 2013, 81, 1042-1042.	1.7	3
40	The Role of Drug-coated Balloons in Infrapopliteal Intervention. US Cardiology Review, 2012, 9, 112-114.	0.5	0
41	Safety and effectiveness of the INVATEC MO.MA® proximal cerebral protection device during carotid artery stenting: Results from the ARMOUR pivotal trial. Catheterization and Cardiovascular Interventions, 2010, 76, 1-8.	1.7	194
42	Evolving Modalities for Femoropopliteal Interventions. Journal of Endovascular Therapy, 2009, 16, II82-II97.	1.5	42
43	The "art―of medicine and the "smokescreen―of the randomized trial offâ€label use of vascular devices. Catheterization and Cardiovascular Interventions, 2008, 72, 998-1002.	1.7	6
44	Carotid stenting with embolic protection: evolutionary advances. Expert Review of Medical Devices, 2008, 5, 427-436.	2.8	7
45	Stents (grafting) should be the primary treatment for symptomatic superficial femoral artery disease. Catheterization and Cardiovascular Interventions, 2007, 69, 886-889.	1.7	1
46	Tibial intervention; no fear!. Catheterization and Cardiovascular Interventions, 2007, 70, 1040-1040.	1.7	0
47	Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial. Catheterization and Cardiovascular Interventions, 2006, 67, 288-297.	1.7	28
48	The Use of Femoropopliteal Stent-Grafts for Critical Limb Ischemia. Techniques in Vascular and Interventional Radiology, 2005, 8, 140-145.	1.0	9
49	Mechanical thrombectomy in peripheral arterial interventions. Journal of Invasive Cardiology, 2004, 16, 10S-14S; quiz 14S-15S.	0.4	0
50	Percutaneous Retrograde Tibial Access in Limb Salvage. Journal of Endovascular Therapy, 2003, 10, 614-618.	1.5	53
51	Clinical results for the training-phase roll-in patients in the intracoil femoralpopliteal stent trial. Catheterization and Cardiovascular Interventions, 2002, 56, 443-449.	1.7	22